BPC-157
Medium EvidenceA pentadecapeptide derived from human gastric juice, studied for tissue repair and gut-protective properties.
What It Is
BPC-157 (Body Protection Compound-157) is a synthetic peptide consisting of 15 amino acids. It is derived from a protein found in human gastric juice. Preclinical studies have investigated its potential role in tissue healing, including tendons, ligaments, muscles, and the gastrointestinal tract. Research has been conducted primarily in animal models, and human clinical data remains limited. As of 2026, only three small human studies have been published, all from a single Florida research group and lacking placebo controls. New 2026 preclinical studies using quantitative histology have found higher satellite cell counts in BPC-157-treated muscle tissue at post-injury days 7 and 14, with treated myofibers showing larger fiber diameters consistent with faster muscle regeneration. In tendon models, researchers documented accelerated tendon fiber organization, increased collagen type I deposition, and measurable upregulation of VEGF and EGF at injury sites. On April 15, 2026, the FDA announced it will convene an advisory panel in July 2026 to review whether BPC-157 and six other restricted peptides can be legally compounded again. This meeting concerns compounding eligibility only — not FDA drug approval. The FDA has opened docket FDA-2025-N-6895 to collect public comments ahead of the July meeting, with a deadline of July 22, 2026 for comments to be presented to the committee (updated from earlier July 9 deadline). The meeting will address 12 peptides total across two sessions (July 2026 and before February 2027). The FDA formally scheduled the Pharmacy Compounding Advisory Committee (PCAC) meeting for July 23–24, 2026 to review BPC-157-related bulk drug substances (BPC-157 free base and BPC-157 acetate) for potential inclusion on the 503A Bulks List. This meeting will also review KPV, TB-500, and MOTS-c. A favorable PCAC outcome would be a significant step toward formal Category 1 reclassification, though formal rulemaking would still be required before compounding pharmacies can legally prepare these substances.
Regulatory Status
Removed from Category 2 (significant safety concerns) effective April 22, 2026 after nomination withdrawal. FDA opened public comment docket (FDA-2025-N-6895) for PCAC review on July 23, 2026 to determine 503A bulks list eligibility. Comments due by July 9, 2026 for committee presentation; docket closes July 22, 2026. Compounding pharmacies may resume 503A compounding pending final PCAC recommendation.
Effective: April 22, 2026
View FDA SourceWhy Researchers Study It
BPC-157 has attracted significant research interest due to its broad tissue-protective effects observed in animal models. Its ability to influence multiple healing pathways — including angiogenesis, nitric oxide synthesis, and growth factor modulation — makes it a compelling subject for preclinical tissue repair studies.
Proposed Mechanisms
- Promotes angiogenesis (new blood vessel formation) at injury sites
- Modulates nitric oxide (NO) system to support vascular function
- Upregulates growth factor receptors (EGF, VEGF) in damaged tissue
- Interacts with the dopaminergic system, potentially influencing gut-brain signaling
- Demonstrates cytoprotective effects on gastric mucosa via multiple pathways
Evidence Snapshot
| Study Type | Model | Outcome | Link |
|---|---|---|---|
| Animal (rat) | Achilles tendon transection | Accelerated tendon healing and functional recovery | Source |
| Animal (rat) | NSAID-induced gastric lesions | Significant reduction in gastric damage scores | Source |
| In vitro | Human fibroblast cultures | Increased cell migration and proliferation rates | Source |
| Animal (rat, 2026) | Skeletal muscle injury — quantitative histology | Higher satellite cell counts at days 7 and 14; larger myofiber diameters indicating faster muscle regeneration; accelerated tendon fiber organization with increased collagen type I and VEGF/EGF upregulation | Source |
Commonly Discussed Benefits
Safety & Cautions
- Most studies are preclinical (animal models)
- Only three small human studies published, all from one research group without placebo controls
- Long-term safety profile not established in humans
- Not FDA-approved for any medical condition
- FDA advisory panel scheduled July 2026 to review compounding eligibility
Comparisons
See how BPC-157 compares to related peptides:
Calculator Tools
Use our research tools to explore dosing and reconstitution data:
Citations
- [1] Sikiric P. et al. — Pentadecapeptide BPC 157 and its role in healing. Curr Pharm Des. 2018 PubMed
- [2] Chang CH. et al. — BPC 157 and its healing properties. J Pharmacol Sci. 2020 PubMed
- [3] BPC-157 Research Results 2026: Preclinical Studies on Tissue Repair — Spartan Peptides PubMed
- [4] FDA PCAC Notice of Meeting: BPC-157 Bulk Drug Substances — Federal Register. April 16, 2026 PubMed
- [5] Regeneration or Risk? A Narrative Review of BPC-157 for Musculoskeletal Healing — PMC 2026 PubMed
- [6] FDA — July 23-24, 2026 Meeting of the Pharmacy Compounding Advisory Committee PubMed
Continue Your Research
Track your research notes and set reminders in the companion app.
Related Peptides
TB-500
Medium EvidenceA naturally occurring peptide involved in cell migration and tissue repair, studied for wound healing and recovery.
GHK-Cu
High EvidenceA naturally occurring copper-binding peptide studied for skin regeneration, wound healing, and anti-aging effects.
KPV
Medium EvidenceA tripeptide derived from alpha-MSH, studied for anti-inflammatory and gut-protective properties.